Article Text
Abstract
Background Evaluating the long term benefit of therapy in multiple sclerosis (MS) is challenging. Although randomised controlled trials (RCTs) demonstrate therapeutic benefits on short term outcomes, the relationship between these outcomes and late disability is not established.
Methods In a patient cohort from the pivotal interferon β-1b trial, the value of clinical and MRI measures were analysed, both at baseline and during the RCT, for predicting long term physical and cognitive outcome.
Results Baseline disability correlated with both physical (R2=0.22; p<0.0001) and cognitive (R2=0.12; p<0.0001) outcome after 16 years. Accrual of disability during the RCT (R2=0.12; p<0.0001) and annualised relapse rates during the trial correlated with physical outcome (R2=0.12; p<0.0001) but not with cognition. In contrast, baseline MRI measures of atrophy and lesion burden correlated with cognitive (R2=0.21; p<0.0001), but not with physical, outcome. Accumulation of plaque burden measured by MRI did not correlate with late physical disability or with cognitive outcome. Multivariate regression analysis using stepwise elimination demonstrated that baseline variables contributed independently to predicting long term outcomes while trial outcome variables contributed little. Overall, and considerably dependent on baseline measures, the models developed by this method accounted for approximately half of the variance in long term cognitive and disability outcome.
Conclusions Although on-trial change in some short term clinical measures correlated with long term physical and disability outcomes, the proportion of the variance explained by single commonly employed on-study variables was often small or undetectable. Better correlations were observed for several baseline measures, suggesting that long term outcome in MS may be largely determined early in the disease course.
Trial registration number http://Clinical Trials.gov, study registration NCT00206635.
Statistics from Altmetric.com
Supplementary materials
Lay Summary 83/3/282
Files in this Data Supplement:
Douglas Goodin discusses the paper in the JNNP podcast
Footnotes
Funding The study was sponsored by Bayer HealthCare Pharmaceuticals. PAREXEL MMS received payment from Bayer HealthCare Pharmaceuticals for editorial support.
Competing interests DSG, GE, AR, DLi, DL, AK, CW, VK and KB have support from Bayer HealthCare for the submitted work, AT has a specified relationship with Bayer HealthCare and might have an interest in submitted work from the previous 3 years. Both the sponsors and the independent investigators were intimately involved in the study design. The researchers DSG, GE, AR, DLi, AT and DL were independent of the funders. The researchers AK, CW, VK and KB either work or previously worked for the funders.
Ethics approval The study obtained ethics approval from the institutional review boards or independent ethics committees of the participating centres before long term follow-up planning, which began in 2004.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Statistical and data tables are available from the corresponding author (douglas.goodin{at}ucsf.edu). Participants gave written informed consent for data acquisition and data sharing.